Mechanism of Action of Sunosi (Solriamfetol)
Sunosi (solriamfetol) works as a selective dopamine and norepinephrine reuptake inhibitor (DNRI) that promotes wakefulness by blocking the reuptake of these neurotransmitters, though the precise mechanism for improving excessive daytime sleepiness remains incompletely understood. 1
Pharmacodynamic Profile
Solriamfetol binds to and inhibits both dopamine and norepinephrine transporters with the following characteristics:
- Dopamine transporter: Low binding affinity (Ki = 14.2 µM) and low potency inhibition (IC50 = 2.9 μM)
- Norepinephrine transporter: Low binding affinity (Ki = 3.7 µM) and low potency inhibition (IC50 = 4.4 μM)
- Serotonin transporter: No appreciable activity (Ki = 81.5 µM; IC50 > 100 μM) 1
This dual reuptake inhibition increases extracellular concentrations of dopamine and norepinephrine in the brain, which is associated with its wake-promoting effects 2.
Key Distinguishing Features
Solriamfetol differs fundamentally from amphetamines in that it lacks monoamine-releasing properties at therapeutic doses 3, 2. This is a critical distinction:
- It does not cause release of dopamine or norepinephrine from presynaptic terminals
- It only blocks reuptake after natural neurotransmitter release
- This mechanism may contribute to a potentially lower abuse liability compared to traditional stimulants, though it remains a Schedule IV controlled substance 4, 3
Receptor Selectivity
Solriamfetol demonstrates no appreciable binding to other neurotransmitter systems, including 1:
- Dopamine, serotonin, or norepinephrine receptors
- GABA, adenosine, or histamine receptors
- Orexin receptors
- Benzodiazepine receptors
- Muscarinic or nicotinic acetylcholine receptors
This selective profile means the wake-promoting effects are mediated specifically through dopamine and norepinephrine transporter inhibition rather than through other arousal systems like histamine or orexin 2.
Clinical Implications
The mechanism translates to clinical efficacy with high-quality evidence supporting its use. The American Academy of Sleep Medicine provides a STRONG recommendation for solriamfetol in treating narcolepsy in adults, based on three RCTs demonstrating clinically significant improvements in excessive daytime sleepiness and disease severity 4. The overall quality of evidence was rated as high 4.
Common Pitfalls to Avoid
- Do not confuse with amphetamine-type stimulants: Solriamfetol's lack of monoamine-releasing effects means it has a different pharmacological profile and potentially different side effect patterns
- Renal elimination is critical: Approximately 95% is excreted unchanged in urine via active tubular secretion, requiring dose adjustments in renal impairment 1
- Minimal metabolism: Unlike many CNS drugs, solriamfetol undergoes minimal hepatic metabolism, making drug-drug interactions through CYP enzymes unlikely 1
The most common adverse events—headache, decreased appetite, insomnia, nausea, and chest discomfort—are generally mild to moderate and occur within the first 2 weeks of treatment 4, 5.